FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1141-1142 April 13, 2000 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: A 10 percent increase in body weight during the first year after organ transplantation is common, and many patients become obese (body-mass index [the weight in kilograms divided by the square of the height in meters], >30) within two years after the procedure.^1,2

In April 1999, the Food and Drug Administration (FDA) approved orlistat for the treatment of obesity. Orlistat partially inhibits the absorption of dietary fat by binding to pancreatic lipase in the gastrointestinal tract. Since its approval, the FDA has received six reports of transplant recipients who had subtherapeutic blood cyclosporine concentrations soon after the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., Eckel, R. H. (2004). Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 110: 2952-2967 [Abstract] [Full Text]